Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.86 +0.77%

+$0.03 today

Market cap
$109.64M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Molecular Partners AGNASDAQ: MOLN

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -CHF 16.51M, compared with -CHF 17.34M a year earlier. Trailing-twelve-month EBITDA was -CHF 63.08M.

Context

  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of -CHF 42.29M (+28.9%) for the fiscal year ending Dec 2026, a step up from the -15.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 16.51M-8.6% QoQ
Last fiscal yearDec 2025
-CHF 59.49M-15.2% YoY
LTMMar 2026
-CHF 63.08M-8.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.8%——
1 year-15.2%+28.9%+44.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

CHF · from the income statement

Latest · FY2025
(59.49M) CHF
Year-over-year change
-15.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How MOLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.3% is the 7th highest of 9, against a peer median of +10.1%.
MOLN Competitors
EBITDA for MOLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$33.38M USD+31.6%—1053.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$37.68M USD+23.9%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$43.73M USD+9.5%—8329.5%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$61.36M USD-27.4%—3439.7%
MOLNMolecular Partners AGLTM Mar 2026-CHF 63.08M CHF-8.3%——
PEPGPepGen Inc.LTM Mar 2026-$75.99M USD+22.0%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.28M USD-67.4%——
NKTXNkarta, Inc.LTM Mar 2026-$90.7M USD+10.7%——
ALECAlector, Inc.LTM Mar 2026-$116.42M USD-1.3%—632.1%
Peer median (excluding MOLN) —+10.1%—2246.5%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.33M189.56M7.04M4.97M0
Cost of Revenue55.72M50.75M47.84M47.5M2.58M
Gross Profit(46.39M)138.81M(40.81M)(42.53M)(2.58M)
Gross Margin-497.2%73.2%-579.8%-855.8%—
Research & Development55.72M50.75M48.78M48.6M40.19M
Selling, General & Admin16.91M21.82M19M17.16M14.87M
Operating Expenses72.75M72.94M20.3M18.68M50.89M
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
EBITDA(60.66M)119M(59.52M)(51.65M)(59.49M)
EBITDA Margin-650.2%62.8%-845.6%-1039.2%—
Operating Income(63.42M)116.61M(61.11M)(61.22M)(58.12M)
Operating Margin-679.7%61.5%-868.3%-1231.7%—
Interest Income108.28K1.2M4.28M3.38M1.52M
Interest Expense608.14K648.12K49K25K18K
Other Income / Expenses(365K)1.24M(876K)7.18M(3.53M)
Income Before Tax(63.78M)117.85M(61.98M)(54.04M)(61.65M)
Pre-Tax Margin-683.6%62.2%-880.7%-1087.3%—
Income Tax Expense2K002K2K
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Net Margin-683.7%62.2%-880.7%-1087.4%—
EPS (Basic)(2.06)3.63(1.89)(1.59)(1.65)
EPS (Diluted)(2.06)3.54(1.89)(1.59)(1.65)
Weighted Avg Shares31.01M32.47M32.77M34.03M37.27M
Weighted Avg Shares (Diluted)31.01M33.27M32.77M34.03M37.27M

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.